Trial Profile
A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ligelizumab (Primary)
- Indications Bullous pemphigoid
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals Corporation
- 14 Oct 2015 Status changed from completed to discontinued as reported by the ClinicalTrials.gov record.
- 14 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 18 Jan 2015 Planned End Date changed from 1 Nov 2015 to 1 Mar 2015 as reported by ClinicalTrials.gov